Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: A EUSTAR analysis

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1743-1748

  Dobrota, Rucsandra ^a,b   Maurer, Britta ^a   Graf, Nicole ^c   Jordan, Suzana ^a   Mihai, Carina ^b   Kowal Bielecka, Otylia ^d   Allanore, Yannick ^e   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Graf Biostatistics   (Switzerland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; CREATINE KINASE; DNA DIRECTED RNA POLYMERASE III; RIBONUCLEOPROTEIN; SCL 70 ANTIBODY;

ADULT; ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MODIFIED RODNAN SKIN SCORE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VALIDATION STUDY; DIFFUSE SCLERODERMA; FIBROSIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; REGISTER; SEVERITY OF ILLNESS INDEX; SKIN; SKIN TEST; STATISTICAL MODEL; TENDON;

ADULT; DISEASE PROGRESSION; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SKIN; SKIN TESTS; TENDONS;

EID: 84962894336     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208024     Document Type: Article

References (17)

1. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7.
2. Wiese AB, Berrocal VJ, Furst DE, et al. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res (Hoboken) 2014;66:1731-9.
3. Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep 2012;14:47-55.
4. Maurer B, Graf N, Michel BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015;74:1124-31.
5. Amjadi S, Maranian P, Furst DE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60: 2490-8.
6. Merkel PA, Silliman NP, Clements PJ, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012;64:3420-9.
7. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
8. Müller-Ladner U, Tyndall A, Czirjak L, et al. Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73:324-7.
9. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
10. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
11. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-9.
12. Valentini G, D'Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
13. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
14. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
15. Furst DE, Clements PJ. D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 2001;30:189-91.
16. Choy T, Baron M, Pope J. Estimating benefits from immunosuppressive treatment in diffuse cutaneous systemic sclerosis: data from the Canadian scleroderma research group. Open J Rheumatol Autoimmune Dis 2014;4:248-53.
17. Sultan N, Pope JE, Clements PJ. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004;43:472-8.